Literature DB >> 22846190

Clinical trial: transcutaneous interferential electrical stimulation in individuals with irritable bowel syndrome - a prospective double-blind randomized study.

Şahin Coban1, Erdem Akbal, Seyfettin Köklü, Gülşah Köklü, Murat Alper Ulaşlı, Serap Erkeç, Bora Aktaş, Osman Yüksel, Erdem Koçak, Hatice Rana Erdem.   

Abstract

BACKGROUND: The exact etiology of irritable bowel syndrome (IBS) remains unclear. Curative treatment is not available and current treatment modalities are mainly directed against the predominant symptoms. There are a few studies reporting the beneficial effects of transcutaneous electrical stimulation in patients with chronic constipation, gastroparesis, and functional dyspepsia. AIM: To investigate whether transcutaneous electrical stimulation is an effective procedure in IBS patients.
METHODS: IBS patients were randomly placed in vacuum interferential current (IFC) and placebo groups. Both treatments consisted of 12 sessions administered over 4 weeks. Symptoms due to IBS were documented via questionnaires, including the IBS Global Assessment of Improvement Scale, numeric rating scales, visual analogue scale, and IBS Quality of Life Scale at the beginning of, end of, and 1 month after the treatment.
RESULTS: Patients in the therapy (29 cases) and placebo (29 cases) groups were homogeneous with respect to demographic data and gastrointestinal system symptoms. When compared to the beginning scores, severity of abdominal discomfort, bloating, and abdominal distension and rumbling improved significantly in either interference or placebo groups at both the end of treatment and 1 month after treatment. In the IFC group, severity of symptoms continued to decrease significantly at 1 month after treatment when compared to scores at just the end of treatment, whereas in the placebo group severity of these symptoms did not change significantly on numeric severity scales. Also, the visual analogue scale of the first month after treatment continued to decrease significantly when compared to the level at the end of treatment in the IFC group. Total quality score increased significantly in the IFC group.
CONCLUSIONS: Vacuum IFC therapy can significantly improve symptoms and quality of life in patients with IBS. It may represent a novel treatment modality for drug-refractory IBS patients.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2012        PMID: 22846190     DOI: 10.1159/000338301

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  6 in total

1.  Management Strategies for Abdominal Bloating and Distension.

Authors:  Anna Foley; Rebecca Burgell; Jacqueline S Barrett; Peter R Gibson
Journal:  Gastroenterol Hepatol (N Y)       Date:  2014-09

Review 2.  Transabdominal electrical stimulation (TES) for the treatment of slow-transit constipation (STC).

Authors:  John M Hutson; Lauren Dughetti; Lefteris Stathopoulos; Bridget R Southwell
Journal:  Pediatr Surg Int       Date:  2015-02-12       Impact factor: 1.827

Review 3.  Irritable Bowel Syndrome: Peripheral Mechanisms and Therapeutic Implications.

Authors:  Iulia-Maria Crişan; Dan Lucian Dumitraşcu
Journal:  Clujul Med       Date:  2014-05-30

Review 4.  Neuromodulation via Interferential Electrical Stimulation as a Novel Therapy in Gastrointestinal Motility Disorders.

Authors:  Judith S Moore; Peter R Gibson; Rebecca E Burgell
Journal:  J Neurogastroenterol Motil       Date:  2018-01-30       Impact factor: 4.924

Review 5.  Neuromodulation in Chronic Pelvic Pain: A Narrative Review.

Authors:  Hao Xiang; Tingting Zhang; Abdullah Al-Danakh; Deyong Yang; Lina Wang
Journal:  Pain Ther       Date:  2022-07-14

6.  The Efficacy and Safety of Transcutaneous Acupoint Interferential Current Stimulation for Cancer Pain Patients With Opioid-Induced Constipation: A Prospective Randomized Controlled Study.

Authors:  Hua-Dong Zhu; Zhen Gong; Bing-Wei Hu; Qiao-Ling Wei; Jun Kong; Cong-Bin Peng
Journal:  Integr Cancer Ther       Date:  2017-10-27       Impact factor: 3.279

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.